NCT00053833终止2 期
S0025: Phase II Trial Of Irinotecan (CAMPTOSAR) For Patients With Platinum And Taxane Refractory Ovarian, Peritoneal Or Fallopian Tube Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 100
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have refractory ovarian epithelial, primary peritoneal, or fallopian tube cancer.
详细描述
OBJECTIVES:
- Determine the objective confirmed and unconfirmed complete and partial response rates of patients with platinum- and taxane-refractory ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with irinotecan.
- Determine the progression-free and overall survival of patients treated with this drug.
- Evaluate the qualitative and quantitative toxic effects of this drug in these patients.
OUTLINE: Patients receive irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
irinotecan
Experimental
irinotecan
干预措施: irinotecan (Drug)
研究者
研究点 (100)
Loading locations...
相似试验
已完成
2 期
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or StomachGastric CancerEsophageal CancerNCT00020761Jonsson Comprehensive Cancer Center51
已完成
2 期
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaLymphomaNCT00003245M.D. Anderson Cancer Center50
已完成
2 期
Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCarcinoma of Unknown PrimaryNeuroendocrine CarcinomaNeuroendocrine Carcinoma of the SkinNCT00004922Memorial Sloan Kettering Cancer Center
已完成
2 期
Irinotecan in Treating Patients With Refractory Metastatic Breast CancerBreast CancerNCT00003351Alliance for Clinical Trials in Oncology104
已完成
2 期
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or SarcomaSarcomaNCT00003955Children's Oncology Group77